Log in

NASDAQ:CVETCovetrus Stock Price, Forecast & News

$15.28
-0.12 (-0.78 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.14
Now: $15.28
$15.77
50-Day Range
$7.51
MA: $11.00
$15.72
52-Week Range
$4.05
Now: $15.28
$26.58
Volume1.43 million shs
Average Volume1.41 million shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.56
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
Current SymbolNASDAQ:CVET
CUSIPN/A
CIKN/A
Phone888-280-2221

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.98 billion
Cash Flow$10.69 per share
Book Value$10.74 per share

Profitability

Net Income$-1,019,000,000.00

Miscellaneous

Employees5,500
Market Cap$1.71 billion
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.

Covetrus (NASDAQ:CVET) Frequently Asked Questions

How has Covetrus' stock been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CVET stock has increased by 69.0% and is now trading at $15.28. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Covetrus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Covetrus.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Covetrus.

How were Covetrus' earnings last quarter?

Covetrus Inc (NASDAQ:CVET) released its earnings results on Thursday, May, 14th. The company reported $0.18 EPS for the quarter, topping the Zacks' consensus estimate of $0.12 by $0.06. The firm earned $1.07 billion during the quarter, compared to the consensus estimate of $1.07 billion. Covetrus had a positive return on equity of 4.84% and a negative net margin of 24.05%. View Covetrus' earnings history.

What guidance has Covetrus issued on next quarter's earnings?

Covetrus updated its first quarter 2020 Pre-Market earnings guidance on Wednesday, April, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.07-1.07 billion, compared to the consensus revenue estimate of $969.68 million.

What price target have analysts set for CVET?

4 brokerages have issued twelve-month price targets for Covetrus' shares. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' stock price to reach $15.50 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View analysts' price targets for Covetrus.

Has Covetrus been receiving favorable news coverage?

Media headlines about CVET stock have trended very negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Covetrus earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutCovetrus.

Are investors shorting Covetrus?

Covetrus saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 15,470,000 shares, a decrease of 15.0% from the April 15th total of 18,210,000 shares. Based on an average daily volume of 1,780,000 shares, the short-interest ratio is presently 8.7 days. Approximately 15.9% of the company's shares are short sold. View Covetrus' Current Options Chain.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include NVIDIA (NVDA), Enterprise Products Partners (EPD), AT&T (T), Verizon Communications (VZ), Evolent Health (EVH), Alphabet (GOOG), IDEXX Laboratories (IDXX), Las Vegas Sands (LVS), Nokia Oyj (NOK) and Pfizer (PFE).

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Benjamin J. Shaw, President, Chief Executive Officer & Director
  • Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
  • Matthew Leonard, Executive VP & President-North America
  • Jim Young, Chief Human Resources Officer & Senior VP
  • Erin Powers Brennan, Secretary, Senior Vice President & General Counsel

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (10.86%), Morgan Stanley (10.84%), BlackRock Inc. (10.69%), Clayton Dubilier & Rice LLC (9.91%), Clearbridge Investments LLC (3.91%) and State Street Corp (2.51%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Edward Mcnamara, Erin Powers Brennan and Timothy Ludlow. View institutional ownership trends for Covetrus.

Which major investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Two Sigma Investments LP, BlackRock Inc., Morgan Stanley, Morgan Stanley, Clayton Dubilier & Rice LLC, Parametric Portfolio Associates LLC, and Gabelli Funds LLC. View insider buying and selling activity for Covetrus.

Which major investors are buying Covetrus stock?

CVET stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Deutsche Bank AG, State Street Corp, Russell Investments Group Ltd., Westside Investment Management Inc., Aigen Investment Management LP, and Brooktree Capital Management. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan. View insider buying and selling activity for Covetrus.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $15.28.

How big of a company is Covetrus?

Covetrus has a market capitalization of $1.71 billion and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis. Covetrus employs 5,500 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is www.henryscheinvet.com.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.